5-Methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile

We are 5-Methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile CAS:138564-59-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:5-Methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile
CAS.NO:138564-59-7
Synonyms:5-Methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile
5-Methyl-2-(2-nitroanilino)-3-thiophenecarbonitrile
5-methyl-2-(2-nitroanilino)thiophene-3-carbonitrile
3-Cyano-5-methyl-2-(2-nitroanilino)thiophene
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 425.4±45.0 °C at 760 mmHg
Molecular Formula C12H9N3O2S
Molecular Weight 259.284
Flash Point 211.1±28.7 °C
 
Specification:
Appearance:Brown to red crystalline powder
Assay:≥97.0%
Loss on drying:≤2.0%
Residue on ignition:≤1.0%
Total impurities:≤3.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Olanzapine(CAS:132539-06-1).

5-Methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile


Related News: “No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise,” said Kristen Devito, Global Director, Catalent Clinical Supply Services.2-Bromo-4-trifluoromethoxyaniline CAS:175278-17-8 Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.40615-36-9 The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.2-(Trifluoromethoxy)benzoic acid CAS:1979-29-9 The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma’s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution.

Related Products
Product Name
2-Bromoacetophenone View Details
HexaMethyleneDiamineTetra (MethylenePhosphonic Acid) View Details
N2-acetyl-L-lysine View Details
2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoic acid manufacturer 3-Cyclopropylmethoxy-4-difluoromethoxybenzoic Acid manufacturer 2-Fluoro-5-iodobenzonitrile manufacturer 2-Butyl Octanedioic acid manufacturer Cytidine-5′-diphosphate disodium salt manufacturer